Natco Pharma Ltd. (NATP)

Currency in INR
814.30
-7.65(-0.93%)
Closed·
NATCOPHARM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
810.00831.60
52 wk Range
773.601,226.80
Key Statistics
Bid/Ask
814.30 / 814.30
Prev. Close
821.95
Open
821.95
Day's Range
810-831.6
52 wk Range
773.6-1,226.8
Volume
559.25K
Average Volume (3m)
574.59K
1-Year Change
-6.3269%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NATCOPHARM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,002.11
Upside
+23.06%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low earnings multiple

Natco Pharma Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

7 Buy
2 Hold
2 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,002.11
(+23.06% Upside)

Natco Pharma Ltd. Earnings Call Summary for Q2/2027

  • NATCO raised FY27 PAT guidance to INR 775-800 crore from INR 700-750 crore despite 30.3% YoY revenue decline driven by lenalidomide erosion.
  • Q2 revenue rose 28.4% sequentially to INR 1,019.4 crore; EBITDA margin held at 30.4% with company maintaining zero debt and INR 2,250 crore net cash.
  • Management expects 10-15% growth in FY28, driven by upcoming launches including carfilzomib (first-to-file), trabectedin, olaparib, and Imbruvica.
  • Brazil revenue surged 66% YoY to INR 121 crore; domestic business improved to INR 130-135 crore quarterly run rate with 15-20% annual growth expected.
  • Shares traded flat at $808, near 52-week low, as investors remain cautious about transition from lenalidomide dependence to diversified product portfolio.
Last Updated: 13-11-2026, 05:08 pm
Read Full Transcript

Earnings

Latest Release
13-11-2026
EPS / Forecast
11.30 / 8.56
Revenue / Forecast
9.67B / 7.51B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 46.26
Dividend Yield
0.52%
Industry Median 0.63%
Annualised payout
4.25
Paid unevenly
5-Years Growth
+3.96%
Growth Streak

NATCOPHARM Income Statement

Compare NATCOPHARM to Peers and Sector

Metrics to compare
NATCOPHARM
Peers
Sector
Relationship
P/E Ratio
19.3x41.2x−0.2x
PEG Ratio
−0.420.550.00
Price/Book
1.6x4.2x2.6x
Price / LTM Sales
5.2x4.7x2.7x
Upside (Analyst Target)
23.1%12.0%72.2%
Fair Value Upside
Unlock1.6%12.4%Unlock

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Employees
4433
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.36M7.83%12.61B
Other Institutional Investors
47.64M24.29%39.09B
Public Companies & Retail Investors
133.16M67.88%109.27B
Total
196.17M100.00%160.98B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Time Cap Pharma Labs Ltd.8.76%1,71,75,4201,40,94,150
Natsoft Information Systems Pvt. Ltd.8.05%1,57,84,9001,29,53,089

FAQ

What Is the Natco Pharma (NATCOPHARM) Share Price Today?

The Natco Pharma share price today is 814.30.

What is the current Natco Pharma (NATCOPHARM) share price and day range?

As of 21-11-2026, the Natco Pharma share price is 814.30, with a previous close of 821.95. The share price has ranged from 810.00 to 831.60 today, while the 52-week range spans from 773.60 to 1,226.80.

What Is the Natco Pharma Market Cap?

As of today, Natco Pharma market cap is 159.74B.

Does Natco Pharma Pay Dividends? What's The Current Dividend Yield?

The Natco Pharma dividend yield is 0.5%%.

What Is the Natco Pharma (NATCOPHARM) Share Price Target?

The average 12-month share price target for Natco Pharma is 1,002.11, with a high estimate of 1240 and a low estimate of 712. 7 analysts recommend buying, while 2 suggest selling, with an overall rating of Buy and +23.06% Upside potential.

What Is Natco Pharma's Earnings Per Share (TTM)?

The Natco Pharma EPS (TTM) is 46.26.

When Is the Next Natco Pharma Earnings Date?

Natco Pharma will release its next earnings report on 17-02-2027.

From a Technical Analysis Perspective, Is NATCOPHARM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Natco Pharma Trade On?

Natco Pharma is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Natco Pharma?

The stock symbol for Natco Pharma is "NATCOPHARM."

How Many Times Has Natco Pharma Stock Split?

Natco Pharma has split 1 times.

How Many Employees Does Natco Pharma Have?

Natco Pharma has 4433 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.